

February 10, 2011



## **MEDIA ADVISORY - Oncolytics Biotech® Inc. to Present at 13th Annual BIO CEO & Investor Conference**

CALGARY, Feb. 10 /PRNewswire-FirstCall/ - Dr. Brad Thompson, President and CEO of Oncolytics Biotech Inc. (TSX: ONC, NASDAQ: ONCY), will present a corporate overview of the Company at the 13<sup>th</sup> Annual BIO CEO & Investor Conference on **Monday, February 14<sup>th</sup>, 2011 at 4:00 p.m. ET**. Hosted by the Biotechnology Industry Organization (BIO), the 13<sup>th</sup> Annual CEO & Investor Conference will take place February 14<sup>th</sup> and 15<sup>th</sup> at the Waldorf-Astoria Hotel in New York.

A live audio link to the webcast presentation is available at:

<http://www.veracast.com/webcasts/bio/ceoinvestor2011/61114431.cfm>, or on the company's website at [www.oncolyticsbiotech.com](http://www.oncolyticsbiotech.com). It is recommended that listeners log on 15 minutes in advance of the presentation to register and download any necessary software.

An audio replay will be accessible approximately one hour following the presentation on the Oncolytics website.

### **About the BIO CEO and Investor Conference**

Now in its thirteenth year, the BIO CEO & Investor Conference 2011 is the largest independent investor conference focused on publicly-traded biotechnology companies. Each year the BIO CEO & Investor Conference provides a neutral forum where institutional investors, industry analysts, and senior biotechnology executives have the opportunity to shape the future investment landscape of the biotechnology industry. The conference features issue-oriented plenary sessions, educational sessions focused on hot therapeutic areas and key business issues, company presentations, one-on-one meetings, and networking opportunities. For more information, visit <http://www.bio.org/bioceo>.

### **About Oncolytics Biotech Inc.**

Oncolytics is a Calgary-based biotechnology company focused on the development of oncolytic viruses as potential cancer therapeutics. Oncolytics' clinical program includes a variety of human trials including a Phase III trial in head and neck cancers using REOLYSIN<sup>®</sup>, its proprietary formulation of the human reovirus. For further information about Oncolytics, please visit: [www.oncolyticsbiotech.com](http://www.oncolyticsbiotech.com).

*The presentation and webcast times are subject to change. This release and the presentation related thereto contain forward-looking statements which involve known and unknown risks, delays, uncertainties and other factors not under the Company's control and which may cause actual results, performance or achievements of the Company to be materially different from the results, performance or expectations implied by these forward-*

*looking statements. Such risks and uncertainties include, among others, the efficacy of REOLYSIN as a cancer treatment, the success and timely completion of clinical studies and trials, uncertainties related to the research and development of pharmaceuticals and uncertainties related to the regulatory process. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned against placing undue reliance on forward-looking statements. The Company does not undertake to update these forward-looking statements, except as required by applicable laws.*

SOURCE Oncolytics Biotech Inc.